GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 12, 2019 (GLOBE NEWSWIRE) — Beyond Air, Inc. (XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, announced today the closing of its previously announced underwritten public offering of 2,620,199 shares of common stock, including 295,199 shares sold pursuant to the underwriters’ partial exercise of their option to purchase additional shares, at a public offering price of $3.66 per share.